DataMeds AI Inc 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OFTHE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026 Or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OFTHE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-42530 DataMeds AI, Inc.(Exact Name of Registrant As Specified In Its Charter) Delaware93-3264234(State or other jurisdiction of(I.R.S. Employerincorporation or organization)Identification No.) (844) 203-6092(Registrant’s telephone number, including area code) Wellgistics Health, Inc.(Former name, former address and former fiscal year, if changed since last report) Securities to be registered under Section 12(b) of the Act: Name of each exchange on which registeredThe Nasdaq Stock Market LLC (The NASDAQ Capital Market) Indicate by check mark whether the registrant (1) has filed reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes☐No☒ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the Company is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒Emerging growth company☒ Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the Company has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act☐ Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of August 17, 2026, there were 3,072,633 shares of the Company’s common stock, par value $0.0001, issued and 3,061,919 sharesoutstanding. TABLE OF CONTENTS PagePart I. Financial Information3Item 1.Financial Statements3Condensed Consolidated Balance Sheets as of June 30, 2026 (unaudited) and December 31, 20253Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2026 and 2025(unaudited)4Condensed Consolidated Statements of Stockholders’ Equity for the Three and Six Months Ended June 30, 2026and 2025 (unaudited)5Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2026 and 2025(unaudited)6Notes to Condensed Consolidated Financial Statements (unaudited)7Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations30Item 3.Quantitative and Qualitative Disclosures About Market Risk42Item 4.Controls and Procedures42Part II. Other Information43Item 1Legal Proceedings43Item 1ARisk Factors43Item 2Unregistered Sales of Equity Securities and Use of Proceeds43Item 3Defaults Upon Senior Securities43Item 4Mine Safety Disclosures43Item 5Other Information43Item 6Exhibits44Signatures45 In this Quarterly Report on Form 10-Q (this “Quarterly Report”), all references to “DataMeds AI, Inc.,” “DataMeds AI,” “we,” “us,”“our” or the “Company” mean DataMeds AI, Inc. (formerly known as Wellgistics Health, Inc.) and its wholly-owned subsidiaries,except where it is made clear that the term means only DataMeds AI, Inc. The Company changed its name from Wellgistics Health,Inc. to DataMeds AI, Inc. effective July 22, 2026, as described in Note 15 — Subsequent Events. The Company’s common stock, parvalue $0.0001 per share, is referred to as “common stock.” DATAMEDS AI, INC.CONSOLIDATED BALANCE SHEETS(Unaudited) LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)Current liabilities: See the accompanying notes to the unaudited condensed consolidated financial statements DATAMEDS AI, INC.CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited) DATAMEDS AI, INC.NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited) Note 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES DataMeds AI, Inc. (formerly known as Wellgistics Health, Inc.) (the “Company,” “we,” “us,” or “our”) is a Delaware corporationheadquartered in Tampa, Florida. The Company was initially organized as Ayan Sponsors LLC on September 6, 2022, andsubsequently incorporated as Danam Health, Inc. on November 15, 2022. On October 4, 2024, the Company changed its corporatename to Wellgistics Health, Inc. by filing a duly authorized Certificate of Amendment to its Certifi